The FDA approves Alzheimer’s drug for use in the U.S.

The Food and Drug Administration approved the use of drugs that aim to reduce the symptoms of Alzheimer’s disease.

The drug is known as lecanemab, although it is sold under the trade name Leqembi and was developed by Eisai Pharmaceuticals.

The FDA approved the drug for use in January, although there are still some clinical trials to be conducted.

“This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer’s disease,” Teresa Buracchio, the director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, said in a statement.

According to data, Alzheimer’s disease affects 6.5 million people in the United States and is an irreversible neurodegenerative disease that slowly destroys memory and the ability to perform everyday tasks.

Following the latest clinical trial of lecanemab, the FDA reported that the results showed a significant reduction in cognitive decline in 1800 participants.

Lecanemab is distributed intravenously, although the drug could cause some adverse effects, such as inflammation or bleeding in the brain, symptoms that some Alzheimer’s patients suffer from, and is known as ARIA.

In view of the side effects, the FDA recommended not prescribing the drug to people who are on anticoagulant medication, as it could increase the risk of cerebral hemorrhage.

This drug should also be used in patients with mild cognitive impairment and in the early stages of the disease.

Leave a Reply

Your email address will not be published. Required fields are marked *